Group 1 - The announcement details the pledge and release of shares by the controlling shareholder, Fosun High Technology, which holds approximately 36.00% of the company's total shares as of August 14, 2025 [2][3] - After the pledge and release, the remaining pledged shares by Fosun High Technology amount to 612,675,000 shares, representing about 22.94% of the company's total shares [2][3] - The controlling shareholder and its concerted parties hold a total of 967,812,180 shares, which is approximately 36.24% of the company's total shares [2][3] Group 2 - As of August 14, 2025, 40,982,500 shares are expected to mature within the next year, accounting for 15.35% of the company's total shares, with a corresponding financing balance of RMB 3.334 billion [7] - The controlling shareholder's operations are normal, and it has the ability to repay debts, with sources including bond issuance and investment returns [7] - The pledge of shares will not adversely affect the company's main business, governance, or management [7] Group 3 - The company participated in a private equity fund, contributing RMB 60 million in the first round of fundraising, which totaled RMB 150 million [11] - The fund's total subscription scale has been reduced from RMB 200 million to RMB 180.5 million due to adjustments by other limited partners [12][15] - Following the reduction, the company's share in the fund will increase to 33.24% from 30% [13][15]
上海复星医药(集团)股份有限公司 关于股东部分股份质押及解除质押的公告